Results 321 to 330 of about 689,752 (349)

Integrin expression in non-small cell carcinoma of the lung [PDF]

Cancer and Metastasis Reviews, 1995
Alteration of integrin expression in a number of different malignant diseases has been recognized, with a trend of downregulation of collagen-laminin binding integrin expression in epithelial tumor types noted. This study evaluated the expression of a panel of integrin subunits that included subunits that form receptors that bind to collagen and ...
W R Smythe, Joseph E. Bavaria, LeBel E, Steven M. Albelda, Larry R. Kaiser   +4 more
openaire   +2 more sources

Some of the next articles are maybe not open access.

Related searches:

Molecular Diagnostics in Non-Small Cell Lung Carcinoma

Seminars in Respiratory and Critical Care Medicine, 2020
AbstractCurrent clinical practice guidelines recognize EGFR, BRAF, ALK, and ROS1 as essential molecular biomarkers, and a host of other genetic alterations as emerging biomarkers for non-small cell lung carcinoma patients. The available approaches to detecting relevant alterations in these genes are diverse and often complementary.
Lynette M. Sholl, Lynette M. Sholl
openaire   +3 more sources

Phase I trial of the HDAC inhibitor LBH589 in combination with sorafenib in patients with renal cell carcinoma, non-small cell lung cancer and soft tissue sarcomas.

Journal of Clinical Oncology, 2012
440 Background: LBH589 is a novel histone deacetylase inhibitor (HDACi) that induces apoptosis of tumor cells. In renal cell carcinoma (RCC) and non-small-cell lung cancer (NSCLC) cell lines, the combination of sorafenib and HDACi was found to have ...
C. Butler, Lydia T Laboccetta, A. Brisendine, T. Keane, C. Sherman, H. Drabkin   +5 more
semanticscholar   +1 more source

Genes and Pathology of Non-Small Cell Lung Carcinoma

Seminars in Oncology, 2014
While histopathology has traditionally been the cornerstone of treatment decisions in the management of lung cancer patients, the complexity and heterogeneity of histological classification has had a limited impact in the routine practice of oncology. This has changed dramatically in the last few years, owing to discoveries of genomic aberrations and ...
Mai Sakashita, Shingo Sakashita, Ming-Sound Tsao, Ming-Sound Tsao   +3 more
openaire   +3 more sources

Curative radiotherapy in non-small cell carcinoma of the lung

International Journal of Radiation Oncology*Biology*Physics, 1990
Recent reports suggest radiotherapy administered to the 5000-6000 cGy level can result in significant long-term survival in non-small cell carcinoma of the lung. This is particularly true for many cases that are technically operable but for medical or other reasons thoracotomy cannot be performed.
William C. Constable, B. M. Talton, C. R. Kersh   +2 more
openaire   +3 more sources

Non-Small-Cell Carcinoma of the Lung

1991
It is estimated that in the United States during 1989, 155000 cases of carcinoma of the lung will occur and that close to 142000 of these patients will die within 1 year from their disease (Silver-Berg and Lubera 1989). At present in the United States, the incidence and death rate from this disease for females has surpassed that for breast cancer in ...
Louis Potters, Marvin Rotman, C. Julian Rosenthal, Hassan Aziz, Mohan Nuthakki   +4 more
openaire   +2 more sources

Therapy for Stage IV Non-Small-Cell Lung Cancer Without Driver Alterations: ASCO and OH (CCO) Joint Guideline Update.

Journal of Clinical Oncology, 2020
PURPOSE The aim of this work is to provide evidence-based recommendations updating the 2017 ASCO guideline on systemic therapy for patients with stage IV non-small-cell lung cancer (NSCLC) without driver alterations.
N. Hanna, B. Schneider, S. Temin, Sherman Baker, J. Brahmer, P. Ellis, L. Gaspar, Rami Y. Haddad, P. Hesketh, D. Jain, I. Jaiyesimi, David H. Johnson, N. Leighl, T. Phillips, Gregory Riely, A. Robinson, R. Rosell, J. Schiller, Navneet Singh, D. Spigel, Janis O Stabler, Joan Tashbar, G. Masters   +22 more
semanticscholar   +1 more source